The final assessment report and related documents concerning OTCA18, 'regional hyperthermia for high-risk soft tissue sarcoma treatment', are now available. The assessed technology is regional hyperthermia added to conventional therapies to treat high-risk soft tissue sarcoma. The objective of this rapid
Open Call for Patient Input for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum (NMOSD) disorders.
Patient group input requested for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum disorders. EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have
EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment. PTJA13 addresses ‘satralizumab indicated for the treatment of patients ≥12 years with neuromyelitis optica spectrum disorders (NMOSD)’, submitted by Roche. We are delighted that INFARMED, EUR (Erasmus
We are pleased to announce that the Final Assessment Report for PTJA07 is now available, with supporting documentation, for access. Please follow this link for full access.
We are pleased to publish the Autumn 2019 issue of EUnetHTA Magazine. Intended for improved accessibility on whichever device you use, this issue includes various contributions from the EUnetHTA member network, while updating information on EUnetHTA products and the state
PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active
We are pleased to announce that the final assessment for OTCA15 “Irreversible electroporation in liver and pancreatic cancer", together with the input from external experts and manufacturers, are now available for access. Irreversible electroporation (IRE) is a nonthermal ablative method based on
We are pleased to roll out the next issue of EUnetHTA Magazine. As we are now experimenting with a web-based format, we hope to provide a more interactive experience for readers, whether that's on desktop, tablet, or mobile device. In this
EUnetHTA is pleased to announced that the document on "Patient Input in Relative Effectiveness Assessments" is now available. The document describes the process regarding direct patient input in REAs within JA3. The document is primarily intended for those who design and
PTJA04 – “Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy” is now available
This is the assessment of the relative effectiveness of ‘Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed